Assessment of plasmatic cell proliferation and apoptosis indexes in the course of multiple myeloma
Authors:
J. Minařík 1; V. Ščudla 1; M. Ordeltová 2; J. Bačovský 1; M. Zemanová 1; T. Pika 1
Authors‘ workplace:
III. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc.
1; Oddělení alergologie a klinické imunologie Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr. Jaromír Bystroň, CSc.
2
Published in:
Vnitř Lék 2008; 54(1): 31-35
Category:
Original Contributions
Overview
Introduction:
The proliferation and apoptosis indexes are a significant prognostic factor in multiple myeloma (MM). The objective of the study was to assess the indexes in the course of MM from the point of view of the disease activity and potential clinical use.
Method:
A sample of 120 patients was studies, of which 49 at diagnosis, 36 in progression and 35 in remission. The proliferation and apoptosis indexes were assessed according to the achieved treatment response and were compared with subsequent progression in patients in remission. The proliferation potential was measured with the propidium-iodide index (PC-PI/CD138), apoptosis was measured with annexine-V (PC-AI/CD138), assessed by the method of flow cytometry.
Results:
The sample of 49 newly diagnosed patients recorded a decrease in PC-PI (M 2.9–2.1, p < 0.0001) and an increase in PC-Al (M 4.7–8.6, p < 0.0001) at remission. Patients without treatment response showed no difference in PC-PI (p = NS), while PC-Al decreased (M 6.2–3.9, p = 0.004). The sample of 36 patients in MM progression with treatment response recorded a decrease in PC-PI (M 2.9–2.2, p < 0.0001) and an increase in PC-Al (M 4.6–8.8, p < 0.019). There was no difference in any of the indicators (p = NS) in cases with zero treatment response. 35 patients in remission with developing progression recorded an increase in PC-Pl (M 2.3–2.7, p < 0.0001) and a decrease in PC-Al (M 8.3–4.2, p < 0.0001).
Conclusion:
The study has shown that monitoring PC-Pl and PC-Al in the course of different phases of MM is beneficial from the point of view of the assessment of changes in the proliferation activity and the degree of apoptosis of myeloma cells. Monitoring the two parametres allows for timely prediction of disease progression.
Keywords:
multiple myeloma – myeloma plasmocytes – proliferation index – apoptosis index – myeloma activity
Sources
1. Caligaris-Cappio F. Biology of the malignant plasma cell. In: Wiernik PH, Goldman JM, Dutcher JP et al. Neoplastic Diseases of the Blood. 4th ed. Cambridge: University Press 2003: 58-73.
2. Desikan R, Jagannath S, Richardson P et al. Multiple myeloma and other plasma cell dyscrasias. In: Pazdur R, Coia LR, Hoskins WJ et al (eds). Cancer Management: A Multidisciplinary Approach. 8th ed. Manhasset (NY): CMP Healthcare Media 2004: 727-745.
3. Greipp PR, Kyle RA Staging, Kinetics and Prognosis in Multiple myeloma. In: Wiernik PH, Goldman JM, Dutcher JP et al. Neoplastic Diseases of the Blood. 4th ed. Cambridge: Cambridge University Press 2003: 488-501.
4. Vacca A, Ribatti D, Roncali L et al. Angiogenesis in B Cell Lymphoproliferative Diseases. Biological and Clinical Studies. Leuk Lymphoma 1995; 20: 27-38.
5. Boccadoro M, Gavarotti P, Fossati G et al. Low plasma cell 3(H) thymidine incorporation in monoclonal gammapathy of undetermined significance (MGUS), smoldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Brit J Haematol 1984; 58: 689-96.
6. Girino M, Riccardi A, Luoni R et al. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammapathies. Acta Haematol 1991; 85: 26-30.
7. Greipp PR, Katzmann JA, O´Fallon M et al. Value of β-2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219-223.
8. San Miguel JF, García-Sanz R Multiple myeloma: differential diagnosis and prognosis. In: Wiernik PH, Goldman JM, Dutcher JP et al. Neoplastic Diseases of the Blood. 4th ed. Cambridge: Cambridge University Press 2003: 179-199.
9. Greipp PR, Kyle RA. Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gammapathy of undetermined significance, and smoldering multiple myeloma. Blood 1983; 62: 166-171.
10. Joshua D, Petersen A, Brown R et al. The labeling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Brit J Haematol 1996; 94: 76-81.
11. Minařík J, Ščudla V, Ordeltová M et al. Evaluation of plasma cell propidium-iodide and annexin-V indices: their relation to prognosis in multiple myeloma. Biomed Pap 2005: 34: 81-84.
12. Scudla V, Ordeltova M, Bacovsky J et al. The relationship between proliferation and apoptosis in patients with monoclonal gammapathy of undetermined significance or multiple myeloma. Haematologica 2005; 90: 1713-1714.
13. Scudla V, Ordeltova M, Minarik J et al. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma. Neoplasma 2006; 53: 199-205.
14. Ščudla V, Ordeltová M, Bačovský J et al. Vyšetření bromdeoxyuridinového indexu u mnohočetného myelomu. I. Vztah k vybraným laboratorním ukazatelům nemoci. Vnitř Lék 1996; 42: 458-463.
15. Ščudla V, Ordeltová M. Vyšetření proliferačních charakteristik u mnohočetného myelomu. II. Vztah ke klinickým a laboratorním ukazatelům nemoci. Hematológia a transfuziológia 1998; 4: 22-28.
16. Witzig TE, Timm M, Larson D et al. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Brit J Haematol 1999; 104: 131-137.
17. Xu JL, Lai R, Kinoshita T et al. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002; 55: 530-534.
18. Maisnar V, Toušková M, Malý J et al. Význam vybraných laboratorních ukazatelů pro diferenciální diagnostiku a sledování aktivity mnohočetného myelomu. Vnitř Lék 2002, 48: 290-297.
19. Fabian P, Křen L, Nenutil R. Assessment of proliferative activity of plasma cells in multiple myeloma. Čes Slov Patol 2004, 39: 46-49.
20. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Brit J Haematol 1998; 102: 1115-1123.
21. Davies FE, Anderson KC. Novel therapeutic targets in multiple myeloma. Eur J Hematol 2000; 64: 359-367.
22. Špička I, Hájek R, VytřasováM et al. Inhibitor proteazomu - bortezomib (Velcade) - v léčbě refrakterního mnohočetného myelomu. První zkušenosti v České republice. Čas Lék Čes 2005; 144: 636-640.
23. Hájek R, Pour L. Bortezomib. Farmakoterapie 2005; 1: 19-21.
24. Greipp PR, Witzig TE, Gonchoroff NJ et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammapathies. Mayo Clin Proc 1987; 62: 969-977.
25. San Miguel JF, Garcia-Sanz R, Gonzales M et al. DNA Cell Content Studies In Multiple Myeloma. Leuk Lymphoma 1996; 23: 33-41.
26. San Miguel JF, Garcia-Sanz R, Gonzales M et al. A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells. Blood 1995; 85: 448-455.
27. Greipp PR, Lust JA, O´Fallon WM et al. Plasma cell labeling index and β-2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 18: 3382-3387.
28. Durie BGM, Salmon SE, Moon TEP Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 1980; 55: 364-371.
29. Adam Z, Bednařík J, Neunauer J et al. Mnohočetný myelom a diferenciální diagnostika bolestí páteře. Doporučení České myelomové skupiny pro včasné vyslovení podezření na mnohočetný myelom a pro včasnou diagnostiku této choroby. Prakt Lék 2006, 86: 396-410.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2008 Issue 1
Most read in this issue
- The use of galactomannan detection in diagnosing invasive aspergilosis in hemato-oncological patients
- Assessment of plasmatic cell proliferation and apoptosis indexes in the course of multiple myeloma
- Statin pharmacokinetics
- Recommendations of Czech Rheumatological Society for the treatment of rheumatoid arthritis. Efficacy and treatment strategies